Skip to main content

Nasal Polyps

12
Pipeline Programs
8
Companies
2
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 4 programs with unclassified modality

On Market (4)

Approved therapies currently available

Roche
XOLAIRApproved
omalizumab
Roche
Anti-IgE [EPC]subcutaneous2003
254M Part D
Merck & Co.
ASMANEX HFAApproved
mometasone furoate
Merck & Co.
inhalation2014
8M Part D
Merck & Co.
ASMANEX TWISTHALERApproved
mometasone furoate
Merck & Co.
inhalation2005
Merck & Co.
ELOCONApproved
mometasone furoate
Merck & Co.
topical1989

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
XOLAIR(Omalizumab)PHASE_3Monoclonal Antibody
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
1
mometasone furoatePHASE_4
MSD
MSDIreland - Ballydine
1 program
1
mometasone furoatePhase 41 trial
Active Trials
NCT01616160Terminated11Est. Jan 2018
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
mometasone furoatePhase 4
ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
1
4
DepemokimabPhase 3Monoclonal Antibody
DepemokimabPhase 3Monoclonal Antibody
MepolizumabPhase 3Monoclonal Antibody
MepolizumabPhase 3Monoclonal Antibody
MepolizumabPhase 2Monoclonal Antibody
Sandoz
SandozAustria - Kundl
1 program
1
Fevipiprant 150 mgPhase 31 trial
Active Trials
NCT03681093Completed98Est. Jun 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDmometasone furoate
SandozFevipiprant 150 mg

Clinical Trials (2)

Total enrollment: 109 patients across 2 trials

NCT01616160MSDmometasone furoate

An Open-label Study to Identify Molecular Markers of Steroid Resistance

Start: Jul 2013Est. completion: Jan 201811 patients
Phase 4Terminated
NCT03681093SandozFevipiprant 150 mg

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Start: Mar 2019Est. completion: Jun 202098 patients
Phase 3Completed

Related Jobs

Scientifc Advisor - Specialty

GSKGSK
Netherlands - Amersfoort
2w ago

Medical Specialist I-Pulmonary-Brooklyn, NY

RegeneronRegeneron
Brooklyn, NY
1mo ago
$144K - $188K/yr

Medical Specialist I-Pulmonology-Dayton, OH/Northern Cincinnati

RegeneronRegeneron
Dayton, OH
2mo ago
$144K - $188K/yr

Medical Specialist I-Pulmonology-West Virginia

RegeneronRegeneron
Charleston, WV
2mo ago
$144K - $188K/yr

Associate Director, Field Medical Affairs - Respiratory (NYC)

RegeneronRegeneron
New York, NY
2mo ago
$176K - $287K/yr

Associate Director, Field Medical Affairs - Respiratory (North Carolina, South Carolina)

RegeneronRegeneron
Remote
2mo ago
$176K - $287K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
Monoclonal Antibody is the dominant modality (100% of programs)
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.